125 I Interstitial Implants in the RIF-1 Murine Flank Tumor: An Animal Model for Brachytherapy
- 31 August 1982
- journal article
- research article
- Published by JSTOR in Radiation Research
- Vol. 91 (3) , 624-637
- https://doi.org/10.2307/3575897
Abstract
The development of a model for interstitial brachytherapy that uses high-activity, removable 125I sources in the RIF-1 murine flank tumor is reported. Experimental end points are clonogenic cell and tumor regrowth delay assays. For the clonogenic cell assay, interstitial radiation is delivered at total doses of 500-10,000 rad at dose rates of 0.9-2.7 rad/min to cells in annuli of tissue in the tumor. Dose-survival curves are characterized by an initial shoulder followed by a straight (exponential) portion, with D0 [mean LD] similar to that of the curve obtained by external irradiation of the RIF-1 tumor in a self-contained Ca irradiator at similar dose rates. Tumor regrowth curves were obtained for minimum tumor doses of 500-5000 rad; marked tumor regression was observed with minimum tumor doses as low as 2000 rad, but results are not as reproducible as the results obtained with the clonogenic cell assay.This publication has 1 reference indexed in Scilit:
- Response of the RIF-1 Tumor In Vitro and in C3H/Km Mice to X-Radiation (Cell Survival, Regrowth Delay, and Tumor Control), Chemotherapeutic Agents, and Activated Macrophages23JNCI Journal of the National Cancer Institute, 1980